HOME >> MEDICINE >> NEWS
Chemotherapy options improve for patients with advanced colorectal cancer

For the first time, researchers have shown that a chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) is as safe and effective as infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) in the first-line treatment of metastatic colorectal carcinoma (MCRC). The findings are reported today at the 2nd ESMO Scientific & Educational Conference (ESEC) in Budapest, Hungary.

"We conducted this phase III study because the combination of oral capecitabine and oxaliplatin showed promising effects in different phase II studies. The idea of this study was to look whether CAPOX can replace the standard treatment of iv. 5-FU/folinic acid in patients with MCRC", said lead author Dr. Hendrik-Tobias Arkenau, from Clinic Bremen East in Germany.

From 2002 to 2004, the authors randomly assigned 476 patients who had not undergone previous chemotherapy to receive either FUFOX (5-fluorouracil (5-FU) 2000mg/m 24h infusion, folinic acid 500mg/m, oxaliplatin 50mg/m d1,8,15,22; q5 wks) or CAPOX (capecitabine 1000mg/m bid d1-14, oxaliplatin 70mg/m d1 and 8; q3 wks).

So far, based on an analysis of 2541 treatment cycles (1026 FUFOX, 1515 CAPOX), both regimens are comparably toxic and showed similar response rates (ITT-RR: 50% FUFOX and 47% CAPOX, p=NS).

Median length of time without progression of disease was 34.7 weeks in the FUFOX arm and 30.3 weeks in the CAPOX arm, respectively, a difference that was not statistically different (p=0.1), the authors found. Additionally, both treatment arms showed similar overall survival, FUFOX 74.9 weeks and CAPOX 70.9 weeks, p=0.72.

The authors conclude that CAPOX shows comparable efficacy and toxicity profiles compared to the FUFOX regimen in patients chemonaive MCRC.

"This study is important for patients because the CAPOX regimen is more convenient to administer. Patients will appreciate needing to come only twice in three weeks as outpatients to receive the 2 hourly oxaliplatin dose. Esp
'"/>

Contact: Gracemarie Bricalli
gracemarie@esmo.org
41-91-973-1911
European Society for Medical Oncology
6-Jun-2005


Page: 1 2

Related medicine news :

1. Chemotherapy with bevacizumab increases risk of blood clots in arteries
2. Chemotherapy may enhance the effectiveness of brain tumor vaccines
3. Chemotherapy more effective when given before breast cancer surgery
4. Chemotherapy temporarily affects the structures of the human brain
5. Chemotherapy gel may fight breast cancer and reduce breast deformity
6. Chemotherapy given directly to the liver improves survival for patients with colorectal cancer
7. Chemotherapy after surgery extends survival for patients with advanced endometrial cancer
8. Chemotherapy errors rare, but have potential for serious consequences
9. Chemotherapy for brain tumors is boosted after vaccine targets resistance-related antigen
10. Asthma study shows patients have more options to control disease
11. Study sheds light on medication treatment options for bipolar disorder

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... Drs. Steven ... whitening in Cornelius, NC. By taking advantage of this offer, valued at more ... every regular six-month hygiene cleaning from the dentist, patients receive a complimentary professional whitening ...
(Date:8/23/2017)... ... ... announced the winners of the Best of the IBA Awards in The 2017 (14th annual) ... 2017 IBAs were not able to apply for the Best of the IBA Awards directly. ... in the IBAs with a Gold Stevie win counting for three points, a Silver Stevie ...
(Date:8/23/2017)... ... 23, 2017 , ... Arizona Spine & Joint Hospital ... designation of High Performing Hospitals by U.S. News & World Report for knee replacement ... significantly better than the national average in a given procedure or condition.  , ...
(Date:8/23/2017)... Nashville, Tennessee (PRWEB) , ... August 23, 2017 ... ... expand its team to support long-term strategic growth plans, announcing the hiring of ... , A certified technology consultant and seasoned sales manager, Keelan will be working ...
(Date:8/22/2017)... BAY AREA, CA (PRWEB) , ... August 22, ... ... Nuvesse, an accessible luxurious collection of unique masks and serums that perfectly fuse ... scientific skin care advancements, at the 2017 Indie Beauty Expo on August 23rd ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: ... immunology, today reports its financial results for the second ... achievements during the second quarter 2017 and to date: ... multiple clinical development programs for the Company,s lead project, ... 3 pivotal study with BL-8040 as novel stem cell ...
(Date:8/7/2017)... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ...  All comparisons, unless otherwise noted, are to the quarter ended ... Second Quarter 2017 Highlights include: Revenue ... 3.5% Total prescriptions dispensed of 220,000, compared ... 7.6% Gross profit per prescription dispensed ...
(Date:8/2/2017)... AROMAS, Calif. , Aug. 2, 2017 /PRNewswire/ ... by Continental Who,s Who as a Pinnacle Lifetime ... currently the Key Account Manager at Turing Pharmaceuticals, ... communications, negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience ...
Breaking Medicine Technology:
Cached News: